Crossing the line: blood transfusion thresholds in ECMO

• by Sasa Rajsic, Joseph E. Tonna, Kiran Shekar

• December 4, 2025

Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

• by Xiurong Yu, Liyu Su, Rong Lu, Shen Zhao, Rongbo Lin, Xianren Ye

• November 19, 2025

Effect of preoperative anemia on surgical outcomes in endonasal transsphenoidal surgery for pituitary adenoma: a matched-cohort study

• by Khor, Wei-Thing, Wong, Chia-En, Chang, Yu, Perng, Pang-Shuo, Lee, Po-Hsuan, Huang, Chi-Chen, Tien, Chih-Hao, Huang, Kuo-Chang, Lee, Jung-Shun

• February 27, 2026

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

• December 17, 2025

• 4 min